These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 12712474

  • 1. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
    Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J.
    Cancer; 2003 May 01; 97(9):2218-24. PubMed ID: 12712474
    [Abstract] [Full Text] [Related]

  • 2. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R.
    Am J Hematol; 2001 Apr 01; 66(4):274-9. PubMed ID: 11279639
    [Abstract] [Full Text] [Related]

  • 3. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK, Gillan E, Quinn JJ, Altman AJ.
    J Pediatr Hematol Oncol; 1998 Apr 01; 20(6):545-7. PubMed ID: 9856675
    [Abstract] [Full Text] [Related]

  • 4. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
    Leoni F, Gianfaldoni G, Annunziata M, Fanci R, Ciolli S, Nozzoli C, Ferrara F.
    Haematologica; 2002 May 01; 87(5):485-9. PubMed ID: 12010661
    [Abstract] [Full Text] [Related]

  • 5. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
    Zhang T, Westervelt P, Hess JL.
    Mod Pathol; 2000 Sep 01; 13(9):954-61. PubMed ID: 11007035
    [Abstract] [Full Text] [Related]

  • 6. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
    Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A.
    Am J Hematol; 2002 Aug 01; 70(4):292-9. PubMed ID: 12210810
    [Abstract] [Full Text] [Related]

  • 7. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    Hu J, Shen ZX, Sun GL, Chen SJ, Wang ZY, Chen Z.
    Int J Hematol; 1999 Dec 01; 70(4):248-60. PubMed ID: 10643151
    [Abstract] [Full Text] [Related]

  • 8. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
    Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Sahara N, Takeshita A, Satoh H, Terada H, Ohno R.
    Leukemia; 2002 Apr 01; 16(4):617-22. PubMed ID: 11960341
    [Abstract] [Full Text] [Related]

  • 9. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW, Zhang GS, Shen JK, Zheng WL, Pei MF, Xu YX, Cao YX, Yi Y, Yang JJ, Peng HL, Zhong HY, Li RJ.
    Acta Haematol; 2009 Apr 01; 121(1):1-8. PubMed ID: 19246888
    [Abstract] [Full Text] [Related]

  • 10. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R, Zucchini P, Galimberti S, Leonardi G, Vaccari P, Donelli A, Luppi M, Petrini M, Torelli G.
    Haematologica; 1999 Nov 01; 84(11):963-8. PubMed ID: 10553155
    [Abstract] [Full Text] [Related]

  • 11. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, Srivastava A, Chandy M, Mathews V.
    Biol Blood Marrow Transplant; 2009 Nov 01; 15(11):1479-84. PubMed ID: 19822309
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
    Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M.
    J Clin Oncol; 2011 Jul 10; 29(20):2753-7. PubMed ID: 21646615
    [Abstract] [Full Text] [Related]

  • 13. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
    Xin L, Wan-jun S, Zeng-jun L, Yao-zhong Z, Yun-tao L, Yan L, Chang-chun W, Qiao-chuan L, Ren-chi Y, Ming-zhe H, Jian-xiang W, Lu-gui Q.
    Leuk Res; 2007 Jun 10; 31(6):765-71. PubMed ID: 17007927
    [Abstract] [Full Text] [Related]

  • 14. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z, Cholovitsh M, Elezovitsh I, Vidovitsh A, Radoshevitsh-Radojkovitsh N, Boshkovitsh D, Novak A, Basara N.
    Srp Arh Celok Lek; 1995 Jun 10; 123(11-12):279-85. PubMed ID: 16296239
    [Abstract] [Full Text] [Related]

  • 15. Management of acute promyelocytic leukemia relapse in the ATRA era.
    Castagnola C, Lunghi M, Corso A, Tajana M, Zappasodi P, Dabusti M, Lazzarino M, Bernasconi C.
    Haematologica; 1998 Aug 10; 83(8):714-7. PubMed ID: 9793255
    [Abstract] [Full Text] [Related]

  • 16. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY, Yang CH, Chen YC.
    Leuk Lymphoma; 2000 Jul 10; 38(3-4):283-93. PubMed ID: 10830735
    [Abstract] [Full Text] [Related]

  • 17. Diagnosis and follow-up of acute promyelocytic leukemia by detection of PML-RAR alpha gene rearrangement.
    Gau JP, Young JH, Lin TH, Yang YS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar 10; 63(3):175-81. PubMed ID: 10746412
    [Abstract] [Full Text] [Related]

  • 18. Early relapse after non myeloablative allogeneic stem cell transplantation in a patient with acute promyelocytic leukemia in complete molecular remission.
    Tavernier E, Thomas X.
    Indian J Cancer; 2003 Mar 10; 40(4):140-3. PubMed ID: 14716110
    [Abstract] [Full Text] [Related]

  • 19. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D, Mistry AR, Solomon E, Guidez F.
    Cancer Treat Res; 2010 Mar 10; 145():219-35. PubMed ID: 20306254
    [Abstract] [Full Text] [Related]

  • 20. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.
    Breccia M, Diverio D, Noguera NI, Visani G, Santoro A, Locatelli F, Damiani D, Marmont F, Vignetti M, Petti MC, Lo Coco F.
    Haematologica; 2004 Jan 10; 89(1):29-33. PubMed ID: 14754603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.